Private Equity, Venture Capital, Finance News and Assistance

NuPathe Inc., a Conshohocken, Penn.-based drug startup focused on neurological and psychiatric disorders, has raised $30 million in Series B funding. Quaker BioVentures and S.R.

BOSTON----Alnara Pharmaceuticals, Inc., a pharmaceutical company developing innovative non-systemic protein therapeutics for the treatment of metabolic and inflammatory diseases, announced today that it has secured $20 million in Series A venture capital financing.

BOSTON----Alnara Pharmaceuticals, Inc., a pharmaceutical company developing innovative non-systemic protein therapeutics for the treatment of metabolic and inflammatory diseases, announced today that it has secured $20 million in Series A venture capital financing.

CAMBRIDGE, Mass.----Link Medicine Corporation, a privately held biotechnology company advancing novel approaches for the treatment of neurodegenerative diseases, announced today that it has obtained $40 million of Series C equity financing to help move its lead preclinical programs into human clinical testing.

CUMBERLAND, R.I.----Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has closed a $20 million Series D equity financing led by Frazier Healthcare Ventures.

InfaCare Pharmaceutical Corporation, a late stage specialty pharmaceutical company focused on the development of products to treat neonatal diseases, today announced a $28 million private placement of its Series B Preferred Stock.

NEW YORK----IRX Therapeutics, a privately-held company dedicated to the discovery and development of proprietary drugs for the treatment of cancer and viral diseases, today announced that it has raised $25 million through a Series A Preferred Stock offering.

Sierra Neuropharmaceuticals, Inc., a formulator of pharmaceuticals for direct-to-the-brain treatment of neurological diseases, announced a $21.5-million venture capital Series A financing.

BURLINGAME, Calif.----APT Pharmaceuticals, a specialty drug development company focused on inhaled treatments for serious lung diseases, announced today the completion of a $32.3 million Series B financing.